Alphamab Oncology to Present the Latest Clinical Data of Anti-HER2 Bispecific ADC JSKN003 at the...

First patient dosed with ADC therapy designed to disrupt tumor blood supply

Enhertu approved in China for patients with previously treated HER2-positive advanced or metastatic gastric cancer

ArriVent licenses ADC from $100M biobuck deal with Aarvik

Mabwell’s Novel Nectin-4 Targeting ADC 9MW2821 Granted Breakthrough Therapy Designation by China’s NMPA